Background: Endotrophin is one of the extracellular matrix proteins secreted by adipose tissue. In this study, we aimed to investigate the effects of changes in blood glucose levels on serum endotrophin levels secreted by adipose tissue and thus on diabetes. Methods: In this prospective pilot study included 78 patients with type 2 diabete (T2D) with hemoglobin A1c level > 9 %. Lifestyle changes were recommended and appropriate medical treatment was initiated to all patients in order to reach the target HbA1c level. Data of anthropometric measurements, urinary albumin creatinine ratio (UACR), serum lipid parameters and endotrophin were collected in patients; all examinations were repeated after 3 months. Analysis was performed using Paired-Samles T test and Spearman tests. Results: Of patients, 23 were female (54.8 %) and 19 were male (45.2 %). Mean age was 55.2 years, with mean diabetes age of 8.14 ± 5.35 years. After 3 months follow-up, HbA1c, fasting glucose, C-reactive protein(CRP), UACR and endotrophin levels were observed to clearly reduce. The variation in serum endotrophin levels examined at the start of the study and in the 3rd month was identified to have a positive correlation with the variation in HbA1c and UACR levels (r = 0.342, p = 0.02; r = 0.484, p = 0.001). Multiple linear regression analysis showed percentage variation values (δ)-endotrophin levels were only independently correlated with (δ)-UACR (model r² = 0.257, p value = 0.00). Conclusions: Endotrophin levels decreased significantly with the decrease in HbA1c. Unexpectedly, this reduction in endotrophin levels is closely related to the decrease in UACR, regardless of blood glucose regulation. We think that studies targeting endotrophin will contribute to the diagnosis, treatment and follow-up of diabetic nephropathy in the future.

Key words: Diabetes mellitus; insulin resistance; oncostatin M; metabolic syndrome

Aim: The study was carried out to investigate the effect of tele-nursing based motivational interviewing on diabetes self-efficacy, self-management, and metabolic control parameters in individuals with Type 2 diabetes. Method: A parallel-group randomized controlled trial. The study was completed with 70 participants (intervention: 36; control: 34). The data were collected using the Socio-demographic and Health Related Questionnaire, the Diabetes Self-Efficacy Scale, the Diabetes Self-Management Scale. The intervention group received eight sessions tele-nursing based motivational interviewing. Instruments were administered to both groups before the intervention, at the end of the last motivational interviewing session (post-test, 3rd-month), and at 6th-month follow-up. The data were analyzed using chi-square test, independent sample t-test, and one-way ANOVA. Results: In the pre-test, there was no difference between the intervention and control groups in terms of independent variables (p > 0.05). Self-efficacy and self-management scores increased in the post-test and follow-up test of the group to which telenursing-based MI was applied, and there was a difference between the groups (p < 0.05). FBG and triglyceride levels of the intervention group decreased significantly in the post-test and follow-up test (FBG = 217.46 ± 73.88, 166.13 ± 50.71, and 161.41 ± 50.50, respectively; triglyceride = 225.28 ± 148.32, 159.68 ± 68.62, and 161.09 ± 73.06, respectively) (p < 0.05). HbA1c% level decreased significantly only in the post-test. However, no significant differences were found in terms of other metabolic parameters (p > 0.05). Conclusions: This result shows the positive effectiveness of tele-nursing based MI intervention on self-efficacy, self-management, HbA1c%, FBG, triglyceride. Public health nurses should be provided with tele-nursing based MI to individuals with type 2 diabetes in primary health care institutions. Study registration. The study was registered in ClinicalTrials NCT05628259 (prospective). Trial registration number and date of registration for prospectively registered trials. The study was registered in ClinicalTrials NCT05628259 (prospective). 2023–02-01.

To determine whether convalescent angiotensin (1−7) peptide replacement therapy with plasma (peptide plasma) transfusion can be beneficial in the treatment of critically ill patients with severe coronavirus 2 (SARS-CoV-2) infection. Case series of 9 critically ill patients with laboratory-confirmed COVID-19 who met the following criteria: severe pneumonia with rapid progression and continuously high viral load despite antiviral treatment. Peptide plasma: Plasma with angiotensin (1−7) content 8–10 times higher than healthy plasma donors was obtained from suitable donors. Peptide plasma transfusion was applied to 9 patients whose clinical status and/or laboratory profile deteriorated and who needed intensive care for 2 days. In our COVID-19 cases, favipiravir, low molecular weight heparin treatment, which is included in the treatment protocol of the ministry of health, was started. Nine patients with oxygen saturation of 93% and below despite nasal oxygen support, whose clinical and/or laboratory deteriorated, were identified. The youngest of the cases was 36 years old, and the oldest patient was 85 years old. 6 of the 9 cases had male gender. 3 cases had been smoking for more than 10 years. 4 cases had at least one chronic disease. In all of our cases, SARS CoV2 lung involvement was bilateral and peptide plasma therapy was administered in cases when oxygen saturation was 93% and below despite nasal oxygen support of 5 liters/minute and above, and intensive care was required. Although it was not reflected in the laboratory parameters in the early period, 8 patients whose saturations improved with treatment were discharged without the need for intensive care. However, a similar response was not obtained in one case. Oxygen requirement increased gradually and, he died in intensive care process. An increase of the platelet count was observed in all cases following the peptide plasma treatment. In this preliminary case series of 9 critically ill patients with COVID-19, administration of plasma containing angiotensin (1−7) was followed by improvement in their clinical status. The limited sample size and study design preclude a definitive statement about the potential effectiveness of this treatment, and these observations require evaluation in clinical trials.